콘텐츠로 건너뛰기
거시경제 📉 부정적

AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough

요약

Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs